FDA is­sues two guid­ances to ac­cel­er­ate Covid-19 treat­ments

6 years ago
FDA+
Coronavirus

Chi­nese biotech aims $232M in IPO cash to push next-gen prostate can­cer drug; Im­munomedics rais­es near­ly a ...

6 years ago
News Briefing

Pos­i­tive piv­otal cell graft da­ta bring No­var­tis-backed Boston biotech step clos­er to fin­ish line

6 years ago
R&D
Cell/Gene Tx

With mon­ey flow­ing, Pli­ant Ther­a­peu­tics heads to pub­lic well

6 years ago
Financing

Mer­ck dou­bles down on Sky­hawk's tech to drug RNA, promis­ing $600M per au­toim­mune, meta­bol­ic tar­get

6 years ago
Deals

Vivek Ra­maswamy’s broth­er, Shankar, spins out on his own, launch­ing au­da­cious gene ther­a­py play

6 years ago
People
Financing

Covid-19 roundup: The FDA gives Mod­er­na’s Covid-19 team a reg­u­la­to­ry em­brace to go along with the cheers and jeers; ...

6 years ago
Coronavirus

Ex-DARPA chief Regi­na Dugan, for­mer Il­lu­mi­na CEO Jay Flat­ley lead $300M Well­come Trust fund to tack­le glob­al health's ...

6 years ago
People

Gen­fit's NASH drug fails a close­ly-watched PhI­II show­down, adding one more set­back to a plagued field

6 years ago
R&D

CEPI bets $384M on No­vavax’s Covid-19 vac­cine — cov­er­ing R&D and man­u­fac­tur­ing in the ground­break­ing race to beat ...

6 years ago
R&D
Coronavirus

Mer­ck to move glob­al head­quar­ters, re­turn­ing to an old home

6 years ago
R&D

Fritz Ger­ber, who led Roche for 2 decades, dies; ADC Ther­a­peu­tics tries again for an IPO, sets terms

6 years ago
News Briefing

'We're good to go': MyoKar­dia clinch­es cru­cial PhI­II win, boost­ing ge­net­ic ap­proach to car­dio R&D

6 years ago
R&D

Small biotech Oys­ter Point sets up pitch to dis­rupt dry eye mar­ket with nasal spray

6 years ago
R&D

Blue­bird takes $200M pay­out from Bris­tol My­ers as Covid-19, BLA de­lays force ex­ecs to bring out the bud­get ax

6 years ago
Deals
FDA+

De­railed by the pan­dem­ic, FDA of­fers CRISPR, Ver­tex drug pro­gram VIP sta­tus for its come­back play

6 years ago
R&D
FDA+

Spun out of George Church's lab, this biotech up­start is map­ping the AAV uni­verse for No­var­tis, Sarep­ta to gaze

6 years ago
Startups
Deals

Top Genen­tech re­searcher steps away and Roche turns to the Broad for a star re­place­ment play­er

6 years ago
People
R&D

As­traZeneca, Mer­ck­'s star PARP in­hibitor Lyn­parza ex­pands reach in ovar­i­an can­cer with new US ap­proval

6 years ago
Pharma
FDA+

A ground­break­ing can­cer drug nabs fast OK, giv­ing Eli Lil­ly boast­ing rights as a ri­val speeds close be­hind

6 years ago
R&D
FDA+

Covid-19 roundup: Charles Riv­er gets slammed by the pan­dem­ic; For­mer Sanofi R&D chief Elias Zer­houni heads a list of ...

6 years ago
Coronavirus

A new play­er en­ters the KRAS game with Fortress; Gilead picks up once-failed can­cer drug from Molo­gen's fire sale

6 years ago
News Briefing

Ovid's lead drug shows promis­ing ef­fi­ca­cy sig­nal in Frag­ile X syn­drome study, but op­ti­mal dos­ing reg­i­men is un­clear ...

6 years ago
R&D

Fresh off pos­i­tive Nu­plazid da­ta, Aca­dia adds new clin­i­cal drug from Van­der­bilt in mile­stone-heavy deal

6 years ago
Deals
First page Previous page 843844845846847848849 Next page Last page
A service from the Financial Times